3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
39
Nivolumab
15
Gemcitabine
8
spartalizumab
7
atezolizumab
7
Carboplatin
7
Cyclophosphamide
6
130-nm albumin-bound paclitaxel
6
durvalumab
5
Cisplatin
5
Bevacizumab
5
fludarabine
4
budigalimab
4
Paclitaxel
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorouracil
4
Cetuximab
4
Albumin-Bound Paclitaxel
4
tislelizumab
3
lenvatinib
3
cemiplimab
3
avelumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Irinotecan
3
HMPL-013
3
Fulvestrant
3
Docetaxel
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Blood Component Removal
×
Gastrointestinal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled